个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS study

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Zhou Qing[1] * ; Zhang He-Long[2] ; Jiang Li-Yan[3] ; Shi Yuan-Kai[4] ; Chen Yuan[5] ; Yu Jin-Ming[6] ; Zhou Cai-Cun[7] ; He Yong[8] ; Hu Yan-Ping[9] ; Liang Zong-An[10] ; Pan Yue-Yin[11] ; Zhuo Wen-Lei[12] ; Song Yong[13] ; Wu Gang[14] ; Chen Gong-Yan[15] ; Lu You[16] ; Zhang Cui-Ying[17] ; Zhang Yi-Ping[18] ; Cheng Ying[19] ; Lu Shun[20] ; Wang Chang-Li[21] ; Zhou Jian-Ying[22] ; Liu Yun-Peng[23] ; He Jian-Xing[24] ; Wang Jie[4] ; Wu Yi-Long[1] ;
机构： [1]Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China. [2]Department of Oncology, Tangdu Hospital, Fourth Military Medical University, Xi'an, China. [3]Department of Respiratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China. [4]Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. [5]Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. [6]Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan, China. [7]Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, Shanghai, China. [8]Department of Respiratory Medicine, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, Chongqing, China. [9]Department of Oncology, Hubei Cancer Hospital, Wuhan, China. [10]Department of Respiratory and Critical Care Medicine, West China School of Medicine and West China Hospital, Sichuan University, Sichuan, China. [11]Department of Oncology, Anhui Medical University, Hefei, China. [12]Department of Oncology, Xinqiao Hospital, The Third Military Medical University, Chongqing, China. [13]Department of Respiration, General Hospital of Eastern Theater Command of Chinese People's Liberation Army, Nanjing, China. [14]Cancer Center, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology, Wuhan, China. [15]Department of Respiration, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China. [16]Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. [17]Cancer Center, Inner Mongolia Autonomous Region People's Hospital, Huhhot, China. [18]Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China. [19]Department of Oncology, Jilin Cancer Hospital, Changchun, China. [20]Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China. [21]Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. [22]Department of Respiratory Disease, Thoracic Disease Center, First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, China. [23]Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China. [24]Department of Thoracic Surgery, Guangzhou Institute for Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
出处：
DOI： 10.1007/s00432-023-04923-8
ISSN：

关键词： Epidermal growth factor receptor T790M Non-small cell lung cancer Osimertinib Real-world

摘要：
ASTRIS study aimed the largest to evaluate the effectiveness and safety of second- or higher-line osimertinib in patients with advanced/metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC) in the real-world setting. Here we report the results of Chinese patients in ASTRIS study.Adults with EGFR T790M-positive advanced NSCLC pretreated with EGFR-tyrosine kinase inhibitor (EGFR-TKI), having a WHO performance status score of 0-2 and asymptomatic, stable central nervous system (CNS) metastases were included. All patients received once-daily osimertinib 80 mg orally. The outcomes included investigator-assessed clinical response, progression-free survival (PFS), time-to-treatment discontinuation (TTD), and safety.A total of 1350 patients were included. Response rate was 55.7% (95% confidence interval [CI] 0.53-0.58). The median PFS and the median TTD were 11.7 months (95% CI 11.1-12.5) and 13.9 months (95% CI 13.1-15.2), respectively. Overall, 389 patients (28.8%) had at least one protocol-specified adverse event (AE); AEs of interstitial lung diseases/pneumonitis-like events and QT prolongation were reported in 3 (0.2%) and 59 (4.4%) patients, respectively.Osimertinib was effective in Chinese patients with T790M-positive NSCLC who had progressed after first- or second-generation EGFR-TKI in real-word setting and the results were consistent with ASTRIS study overall population and AURA studies. No new safety signals or events were identified.NCT02474355.© 2023. The Author(s).

基金：
AstraZeneca (S.dert.lje, Sweden)
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 3 区 医学
小类 | 4 区 肿瘤学
最新[2023]版：
大类 | 3 区 医学
小类 | 4 区 肿瘤学
JCR分区：
出版当年[2023]版：
Q3 ONCOLOGY
最新[2023]版：
Q3 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
通讯作者：
推荐引用方式(GB/T 7714)：
Zhou Qing,Zhang He-Long,Jiang Li-Yan,et al.Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS study[J].JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY.2023,149(12):10771-10780.doi:10.1007/s00432-023-04923-8.
APA：
Zhou Qing,Zhang He-Long,Jiang Li-Yan,Shi Yuan-Kai,Chen Yuan...&Wu Yi-Long.(2023).Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS study.JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY,149,(12)
MLA：
Zhou Qing,et al."Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS study".JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 149..12(2023):10771-10780

相关文献

[1]医院后勤精细化管理策略研究 [2]个性化目标教学在神经外科护理实习生带教中的应用 [3]纳米增强免疫比浊法和高效液相色谱法检测化疗患者5-氟尿嘧啶血药浓度的比较 [4]徒手淋巴引流对乳腺癌术后淋巴水肿的治疗效果分析 [5]护理干预在减轻妇科恶性肿瘤腹部术后疼痛中的效果 [6]心理护理对肿瘤介入治疗患者生活质量的影响 [7]某院2400张门诊中成药处方分析 [8]人文关怀在恶性肿瘤护理中的应用效果分析 [9]综合护理干预对肺癌化疗患者生活质量的影响 [10]外涂万花油对化疗性静脉炎的预防及疗效

资源点击量：52801 今日访问量：0 总访问量：4559 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号